Cargando…

MALDI-TOF Protein Profiling Reflects Changes in Type 1 Diabetes Patients Depending on the Increased Amount of Adipose Tissue, Poor Control of Diabetes and the Presence of Chronic Complications

Introduction: Protein profiling allows the determination of the presence of proteins marking various stages of the disease, and differentiates between people at risk of various diseases. In type 1 diabetes, protein profiling had been previously used to find blood markers other than islet autoantibod...

Descripción completa

Detalles Bibliográficos
Autores principales: Zawada, Agnieszka, Naskręt, Dariusz, Matuszewska, Eliza, Kokot, Zenon, Grzymisławski, Marian, Zozulińska-Ziółkiewicz, Dorota, Dobrowolska, Agnieszka, Matysiak, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967698/
https://www.ncbi.nlm.nih.gov/pubmed/33668851
http://dx.doi.org/10.3390/ijerph18052263
_version_ 1783665937467047936
author Zawada, Agnieszka
Naskręt, Dariusz
Matuszewska, Eliza
Kokot, Zenon
Grzymisławski, Marian
Zozulińska-Ziółkiewicz, Dorota
Dobrowolska, Agnieszka
Matysiak, Jan
author_facet Zawada, Agnieszka
Naskręt, Dariusz
Matuszewska, Eliza
Kokot, Zenon
Grzymisławski, Marian
Zozulińska-Ziółkiewicz, Dorota
Dobrowolska, Agnieszka
Matysiak, Jan
author_sort Zawada, Agnieszka
collection PubMed
description Introduction: Protein profiling allows the determination of the presence of proteins marking various stages of the disease, and differentiates between people at risk of various diseases. In type 1 diabetes, protein profiling had been previously used to find blood markers other than islet autoantibodies to indicate the pancreatic beta cell destruction process and to reflect the progression of type 1 diabetes mellitus (T1DM). However, T1DM is an auto-immune disease and its clinical presentation changes in time of its duration. The aim of the study: To find differences in protein profiles in patients with type 1 diabetes according to diabetes control (HbA1c > 7%) and with presence of diabetic complications or obesity. It may help to identify subgroups of patients who may need a better clinical supervision and individualized treatment. Material and methods: A group of 103 patients with auto-immunologically confirmed T1DM, and meeting the following inclusion criteria: Caucasian race, duration of diabetes >5 years, were used in the study. Criteria of exclusion: past or present cancer (treated with chemo-/radiotherapy), diseases of the liver (ALT > 3 × ULN) except for people with simple hepatic steatosis, chronic renal disease (eGFR < 30 mL/1.73 m(2)/min), and acute inflammation (CRP > 5 mg/dL). The study group was divided in terms of the presence of chronic complications, obesity, or poor metabolic control (HbA1c > 7%). Protein profiling was completed by using the MALDI-TOF MS (matrix-assisted laser desorption/ionization-time of flight mass spectrometry) analyzer. Results: Differentiating proteins were identified in all of the groups. The groups burdened with complications, obesity, and poor metabolic control were characterized by increased levels of fibrinogen, complement C4 and C3. Conclusion: The groups of type 1 diabetes patients burdened with complications, obesity, and poor metabolic control were characterized by increased levels of fibrinogen, complement C4 and C3. Further detailed studies are necessary to determine more subtle changes in the proteomic profile of patients with type 1 diabetes.
format Online
Article
Text
id pubmed-7967698
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79676982021-03-18 MALDI-TOF Protein Profiling Reflects Changes in Type 1 Diabetes Patients Depending on the Increased Amount of Adipose Tissue, Poor Control of Diabetes and the Presence of Chronic Complications Zawada, Agnieszka Naskręt, Dariusz Matuszewska, Eliza Kokot, Zenon Grzymisławski, Marian Zozulińska-Ziółkiewicz, Dorota Dobrowolska, Agnieszka Matysiak, Jan Int J Environ Res Public Health Article Introduction: Protein profiling allows the determination of the presence of proteins marking various stages of the disease, and differentiates between people at risk of various diseases. In type 1 diabetes, protein profiling had been previously used to find blood markers other than islet autoantibodies to indicate the pancreatic beta cell destruction process and to reflect the progression of type 1 diabetes mellitus (T1DM). However, T1DM is an auto-immune disease and its clinical presentation changes in time of its duration. The aim of the study: To find differences in protein profiles in patients with type 1 diabetes according to diabetes control (HbA1c > 7%) and with presence of diabetic complications or obesity. It may help to identify subgroups of patients who may need a better clinical supervision and individualized treatment. Material and methods: A group of 103 patients with auto-immunologically confirmed T1DM, and meeting the following inclusion criteria: Caucasian race, duration of diabetes >5 years, were used in the study. Criteria of exclusion: past or present cancer (treated with chemo-/radiotherapy), diseases of the liver (ALT > 3 × ULN) except for people with simple hepatic steatosis, chronic renal disease (eGFR < 30 mL/1.73 m(2)/min), and acute inflammation (CRP > 5 mg/dL). The study group was divided in terms of the presence of chronic complications, obesity, or poor metabolic control (HbA1c > 7%). Protein profiling was completed by using the MALDI-TOF MS (matrix-assisted laser desorption/ionization-time of flight mass spectrometry) analyzer. Results: Differentiating proteins were identified in all of the groups. The groups burdened with complications, obesity, and poor metabolic control were characterized by increased levels of fibrinogen, complement C4 and C3. Conclusion: The groups of type 1 diabetes patients burdened with complications, obesity, and poor metabolic control were characterized by increased levels of fibrinogen, complement C4 and C3. Further detailed studies are necessary to determine more subtle changes in the proteomic profile of patients with type 1 diabetes. MDPI 2021-02-25 /pmc/articles/PMC7967698/ /pubmed/33668851 http://dx.doi.org/10.3390/ijerph18052263 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Zawada, Agnieszka
Naskręt, Dariusz
Matuszewska, Eliza
Kokot, Zenon
Grzymisławski, Marian
Zozulińska-Ziółkiewicz, Dorota
Dobrowolska, Agnieszka
Matysiak, Jan
MALDI-TOF Protein Profiling Reflects Changes in Type 1 Diabetes Patients Depending on the Increased Amount of Adipose Tissue, Poor Control of Diabetes and the Presence of Chronic Complications
title MALDI-TOF Protein Profiling Reflects Changes in Type 1 Diabetes Patients Depending on the Increased Amount of Adipose Tissue, Poor Control of Diabetes and the Presence of Chronic Complications
title_full MALDI-TOF Protein Profiling Reflects Changes in Type 1 Diabetes Patients Depending on the Increased Amount of Adipose Tissue, Poor Control of Diabetes and the Presence of Chronic Complications
title_fullStr MALDI-TOF Protein Profiling Reflects Changes in Type 1 Diabetes Patients Depending on the Increased Amount of Adipose Tissue, Poor Control of Diabetes and the Presence of Chronic Complications
title_full_unstemmed MALDI-TOF Protein Profiling Reflects Changes in Type 1 Diabetes Patients Depending on the Increased Amount of Adipose Tissue, Poor Control of Diabetes and the Presence of Chronic Complications
title_short MALDI-TOF Protein Profiling Reflects Changes in Type 1 Diabetes Patients Depending on the Increased Amount of Adipose Tissue, Poor Control of Diabetes and the Presence of Chronic Complications
title_sort maldi-tof protein profiling reflects changes in type 1 diabetes patients depending on the increased amount of adipose tissue, poor control of diabetes and the presence of chronic complications
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967698/
https://www.ncbi.nlm.nih.gov/pubmed/33668851
http://dx.doi.org/10.3390/ijerph18052263
work_keys_str_mv AT zawadaagnieszka malditofproteinprofilingreflectschangesintype1diabetespatientsdependingontheincreasedamountofadiposetissuepoorcontrolofdiabetesandthepresenceofchroniccomplications
AT naskretdariusz malditofproteinprofilingreflectschangesintype1diabetespatientsdependingontheincreasedamountofadiposetissuepoorcontrolofdiabetesandthepresenceofchroniccomplications
AT matuszewskaeliza malditofproteinprofilingreflectschangesintype1diabetespatientsdependingontheincreasedamountofadiposetissuepoorcontrolofdiabetesandthepresenceofchroniccomplications
AT kokotzenon malditofproteinprofilingreflectschangesintype1diabetespatientsdependingontheincreasedamountofadiposetissuepoorcontrolofdiabetesandthepresenceofchroniccomplications
AT grzymisławskimarian malditofproteinprofilingreflectschangesintype1diabetespatientsdependingontheincreasedamountofadiposetissuepoorcontrolofdiabetesandthepresenceofchroniccomplications
AT zozulinskaziołkiewiczdorota malditofproteinprofilingreflectschangesintype1diabetespatientsdependingontheincreasedamountofadiposetissuepoorcontrolofdiabetesandthepresenceofchroniccomplications
AT dobrowolskaagnieszka malditofproteinprofilingreflectschangesintype1diabetespatientsdependingontheincreasedamountofadiposetissuepoorcontrolofdiabetesandthepresenceofchroniccomplications
AT matysiakjan malditofproteinprofilingreflectschangesintype1diabetespatientsdependingontheincreasedamountofadiposetissuepoorcontrolofdiabetesandthepresenceofchroniccomplications